ASCO 2025: Multimodal Artificial Intelligence (MMAI) Model to Identify Benefit from 2nd ... - UroToday
ASCO 2025 multimodal artificial intelligence (MMAI) model, androgen receptor pathway inhibitors (ARPI), high- risk non-metastatic prostate cancer, ...
Read the original at UroToday ↗
- Topics
- Healthcare
- Tracked via
- “AI Risks”